vs
Side-by-side financial comparison of Merchants Bancorp (MBIN) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $175.2M, roughly 1.7× Merchants Bancorp). Merchants Bancorp runs the higher net margin — 38.6% vs 12.8%, a 25.8% gap on every dollar of revenue. Over the past eight quarters, Merchants Bancorp's revenue compounded faster (4.8% CAGR vs 4.2%).
Ameris Bancorp is an American bank holding company headquartered in Atlanta, Georgia. Through its bank subsidiary, Ameris Bank, the company operates full-service branches in Georgia, Alabama, Florida, North Carolina and South Carolina, and mortgage-only locations in Georgia, Alabama, Florida, North Carolina, South Carolina, Virginia, Maryland, and Tennessee. The company offers online and mobile banking options for both consumers and businesses.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
MBIN vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $175.2M | $295.9M |
| Net Profit | $67.7M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 38.6% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | 16.3% | 68.3% |
| EPS (diluted) | $1.25 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $175.2M | — | ||
| Q4 25 | $185.3M | $295.9M | ||
| Q3 25 | $171.1M | — | ||
| Q2 25 | $179.2M | $317.0M | ||
| Q1 25 | $145.9M | $316.2M | ||
| Q4 24 | $193.8M | $297.0M | ||
| Q3 24 | $149.6M | $289.5M | ||
| Q2 24 | $159.5M | $306.1M |
| Q1 26 | $67.7M | — | ||
| Q4 25 | — | $38.0M | ||
| Q3 25 | $54.7M | — | ||
| Q2 25 | $38.0M | $-17.7M | ||
| Q1 25 | $58.2M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $61.3M | $33.6M | ||
| Q2 24 | $76.4M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 39.9% | 18.4% | ||
| Q3 25 | 37.8% | — | ||
| Q2 25 | 27.3% | -7.5% | ||
| Q1 25 | 52.4% | 12.2% | ||
| Q4 24 | 66.0% | 16.0% | ||
| Q3 24 | 54.4% | 13.8% | ||
| Q2 24 | 62.2% | 15.0% |
| Q1 26 | 38.6% | — | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | 32.0% | — | ||
| Q2 25 | 21.2% | -5.6% | ||
| Q1 25 | 39.9% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 41.0% | 11.6% | ||
| Q2 24 | 47.9% | 13.3% |
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.28 | $0.24 | ||
| Q3 25 | $0.97 | — | ||
| Q2 25 | $0.60 | $-0.11 | ||
| Q1 25 | $0.93 | $0.14 | ||
| Q4 24 | $1.84 | $0.22 | ||
| Q3 24 | $1.17 | $0.21 | ||
| Q2 24 | $1.49 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $83.2M | $172.9M |
| Total DebtLower is stronger | $32.0M | $260.0M |
| Stockholders' EquityBook value | $2.3B | $2.0B |
| Total Assets | $20.3B | $2.5B |
| Debt / EquityLower = less leverage | 0.01× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $83.2M | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | $32.0M | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $2.0B | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | $1.9B | ||
| Q1 25 | $2.2B | $2.0B | ||
| Q4 24 | $2.2B | $2.1B | ||
| Q3 24 | $1.9B | $2.1B | ||
| Q2 24 | $1.9B | $2.1B |
| Q1 26 | $20.3B | — | ||
| Q4 25 | $19.4B | $2.5B | ||
| Q3 25 | $19.4B | — | ||
| Q2 25 | $19.1B | $2.6B | ||
| Q1 25 | $18.8B | $2.6B | ||
| Q4 24 | $18.8B | $2.7B | ||
| Q3 24 | $18.7B | $2.7B | ||
| Q2 24 | $18.2B | $2.7B |
| Q1 26 | 0.01× | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MBIN
| Net Interest Income | $128.6M | 73% |
| Noninterest Income | $46.6M | 27% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
